text
stringlengths
0
146
• Non-invasive;
• Carcinoma-in-situ (Tis)
or Ta;
• Having borderline
malignancy;
• Having any degree of
malignant potential;
• Having suspicious
malignancy;
• Neoplasm of uncertain
or unknown behavior; or
• All grades of dysplasia,
squamous intraepithelial
lesions (HSIL and LSIL)
and intra epithelial
neoplasia;
B) Any non-melanoma
skin carcinoma, skin
confined primary
cutaneous lymphoma and
dermatofibrosarcoma
protuberans unless there
is evidence of metastases
to lymph nodes or beyond;
C) Malignant melanoma
that has not caused
invasion beyond the
epidermis;
D) All Prostate cancers
histologically described as
T1N0M0 (TNM
Classification) or below; or
Prostate cancers of
another equivalent or
lesser classification;
E) All Thyroid cancers
histologically classified as
T1N0M0 (TNM
Classification) or below;
F) All Neuroendocrine
tumours histologically
classified as T1N0M0
(TNM Classification) or
below;
G) All tumours of the
Urinary Bladder
histologically classified as
T1N0M0 (TNM
Classification) or below;
H) All Gastro-Intestinal
Stromal tumours
histologically classified as
Stage I or IA according to
the latest edition of the
AJCC Cancer Staging
Manual, or below;
I) Chronic Lymphocytic
Leukaemia less than RAI
Stage 3;
Manulife CI FlexiCare (Deluxe) v0123
Page 23 of 42
Manulife (Singapore) Pte. Ltd.
A Manulife Company
Conditions
Early Stage
transplant or other major
interventionist treatment.
The diagnosis of the
above minor cancers must
be established by
histological evidence and
be confirmed by a
specialist in the relevant
field.
The following conditions
are specifically excluded
from coverage:
• Clinical diagnosis
• Any diagnosis on the
basis of finding tumour
cells and/or tumorassociated molecules in
blood, saliva, faeces,
urine or any other bodily
fluid in the absence of
further definitive and
clinically verifiable
evidence does not meet
the above definition.
• Any lesion or tumour
which is histologically
described as benign,
dysplasia, premalignant,
borderline malignant, or
suspicious malignant
potential.
• Cervical Dysplasia, CIN1, CIN-2 and CIN-3 and